Inventor · disambiguated record
Jeffrey Charles Way
Also filed as: WAY JEFFREY · WAY JEFFREY C · WAY JEFFREY CHARLES
32 granted patents·21 pending applications·292 citations·filing 1998–2025
97Inventor score
Top patents by PatentIndex Score
53 records- 0197US11203623B2Engineered opsonin for pathogen detection and treatmentHARVARD COLLEGE·Filed 2020·Granted Dec 21, 2021·4 cites·17 claims
- 0297US9150631B2Engineered opsonin for pathogen detection and treatmentSUPER MICHAEL·Filed 2011·Granted Oct 6, 2015·49 cites·15 claims
- 0396US11795212B2Engineered microbe-targeting molecules and uses thereofHARVARD COLLEGE·Filed 2020·Granted Oct 24, 2023·4 cites·23 claims
- 0495US8066994B2Proteins comprising an IgG2 domainGILLIES STEPHEN D·Filed 2006·Granted Nov 29, 2011·25 cites·13 claims
- 0595US7589179B2IL-7 variants with reduced immunogenicityMERCK PATENT GMBH·Filed 2005·Granted Sep 15, 2009·40 cites·8 claims
- 0694US7211253B1Erythropoietin forms with improved propertiesMERCK PATENTGMBH·Filed 2000·Granted May 1, 2007·48 cites·18 claims
- 0793US9593160B2Engineered microbe-targeting molecules and uses thereofINGBER DONALD E·Filed 2012·Granted Mar 14, 2017·27 cites·18 claims
- 0892US10221250B2Internalizing moietiesVALERION THERAPEUTICS LLC·Filed 2015·Granted Mar 5, 2019·6 cites·16 claims
- 0992US7601814B2Reducing the immunogenicity of fusion proteinsMERCK PATENT GMBH·Filed 2005·Granted Oct 13, 2009·10 cites·7 claims
- 1091US7189830B2Anti-KSA/IL-2 fusion proteins with reduced immunogenicityMERCK PATENT GMBH·Filed 2002·Granted Mar 13, 2007·29 cites·1 claims
- 1189US10865235B2Engineered microbe-targeting molecules and uses thereofHARVARD COLLEGE·Filed 2019·Granted Dec 15, 2020·2 cites·18 claims
- 1289US10017581B2Methods and compositions for treatment of Pompe diseaseVALERION THERAPEUTICS LLC·Filed 2014·Granted Jul 10, 2018·12 cites·32 claims
- 1389US7820155B2Methods of treating cancer comprising administering an interleukin-6 antibody variable regionMERCK PATENT GMBH·Filed 2006·Granted Oct 26, 2010·11 cites·2 claims
- 1486US2024309074A1Engineered microbe-targeting molecules and uses thereofHARVARD COLLEGE·Filed 2023·Application pending·0 cites
- 1585US10047405B2Engineered genetic enteric sensor bacteria and uses thereofHARVARD COLLEGE·Filed 2014·Granted Aug 14, 2018·4 cites·20 claims
- 1685US7973150B2Reducing the immunogenicity of fusion proteinsMERCK PATENT GMBH·Filed 2009·Granted Jul 5, 2011·3 cites·2 claims
- 1783US10385367B2Methods and molecules for yield improvement involving metabolic engineeringWAY JEFFREY C·Filed 2010·Granted Aug 20, 2019·7 cites·27 claims
- 1881US11059873B2Engineered opsonin for pathogen detection and treatmentHARVARD COLLEGE·Filed 2019·Granted Jul 13, 2021·0 cites·21 claims
- 1981US8926973B2Reducing the immunogenicity of fusion proteinsGILLIES STEPHEN D·Filed 2011·Granted Jan 6, 2015·2 cites·4 claims
- 2081US7615217B2Artificial proteins with reduced immunogenicityMERCK PATENT GMBH·Filed 2007·Granted Nov 10, 2009·3 cites·6 claims
- 2180US2022056089A1Engineered opsonin for pathogen detection and treatmentHARVARD COLLEGE·Filed 2021·Application pending·0 cites
- 2275US11059874B2Engineered opsonin for pathogen detection and treatmentHARVARD COLLEGE·Filed 2020·Granted Jul 13, 2021·0 cites·23 claims
- 2374US12331334B2Modified urokinase-type plasminogen activator polypeptides and methods of useVERTEX PHARMA·Filed 2023·Granted Jun 17, 2025·0 cites·65 claims
- 2474US8536308B2Antibodies to interleukin-6WAY JEFFREY·Filed 2010·Granted Sep 17, 2013·4 cites·9 claims
- 2568US11014973B2Fusion proteins for treating cancer and related methodsHARVARD COLLEGE·Filed 2019·Granted May 25, 2021·0 cites·24 claims
- 2668US10538562B2Engineered opsonin for pathogen detection and treatmentHARVARD COLLEGE·Filed 2017·Granted Jan 21, 2020·0 cites·5 claims
- 2767US10308697B2Fusion proteins for treating cancer and related methodsHARVARD COLLEGE·Filed 2015·Granted Jun 4, 2019·1 cites·16 claims
- 2866US2025136965A1Complement factor i-related compositions and methodsVERTEX PHARMA·Filed 2024·Application pending·0 cites
- 2966US2025263683A1Modified urokinase-type plasminogen activator polypeptides and methods of useVERTEX PHARMA·Filed 2025·Application pending·0 cites
- 3062US2007274991A1Treatment of tumors expressing mutant EGF receptorsWAY JEFFREY C·Filed 2007·Application pending·0 cites
- 3162US2024287150A1Methods and compositions relating to tissue-protective erythropoietinHARVARD COLLEGE·Filed 2022·Application pending·0 cites
- 3261US10526399B2Engineered microbe-targeting molecules and uses thereofHARVARD COLLEGE·Filed 2017·Granted Jan 7, 2020·0 cites·6 claims
- 3361US2024228585A1Fc-fusion protein therapeutic for the treatment of pancreatitisHARVARD COLLEGE·Filed 2022·Application pending·0 cites
- 3460US10703824B2Internalizing moietiesVALERION THERAPEUTICS LLC·Filed 2019·Granted Jul 7, 2020·0 cites·13 claims
- 3560US2015141626A1Reducing the immunogenicity of fusion proteinsMERCK PATENT GMBH·Filed 2015·Application pending·0 cites
- 3659US12116606B2Complement factor I-related compositions and methodsVERTEX PHARMA·Filed 2021·Granted Oct 15, 2024·0 cites·20 claims
- 3759US10907221B2Engineered genetic enteric sensor bacteria and uses thereofHARVARD COLLEGE·Filed 2018·Granted Feb 2, 2021·0 cites·10 claims
- 3859US2016200785A1Engineered opsonin for pathogen detection and treatmentHARVARD COLLEGE·Filed 2015·Application pending·0 cites
- 3958US10538566B2Fusion proteins for treating cancer and related methodsHARVARD COLLEGE·Filed 2019·Granted Jan 21, 2020·0 cites·11 claims
- 4058US2009311803A1Treatment Of Tumors Expressing Mutant EGF ReceptorsWAY JEFFREY C·Filed 2009·Application pending·0 cites
- 4156US2005202538A1Fc-erythropoietin fusion protein with improved pharmacokineticsMERCK PATENT GMBH·Filed 2004·Application pending·0 cites
- 4254US2005069521A1Enhancing the circulating half-life of interleukin-2 proteinsEMD LEXIGEN RES CT CORP·Filed 2004·Application pending·0 cites
- 4352US11613744B2Modified urokinase-type plasminogen activator polypeptides and methods of useVERTEX PHARMA·Filed 2020·Granted Mar 28, 2023·0 cites·77 claims
- 4452US2022282263A1Engineered organisms and uses thereof in the production of biologics, reagents, diagnostics and research tools64 X INC·Filed 2020·Application pending·0 cites
- 4552US2022228104A1Engineered organisms and uses thereof as living medicines, research tools, food products, or environmental tools64 X INC·Filed 2020·Application pending·0 cites
- 4650US2018251571A1Methods and compositions for treatment of pompe diseaseVALERION THERAPEUTICS LLC·Filed 2018·Application pending·0 cites
- 4748US2003003513A1Compounds and methods for the inhibition of protein-protein interactionsFiled 2002·Application pending·0 cites
- 4848US2022098261A1Methods and compositions relating to improved forms of targeted erythropoietinHARVARD COLLEGE·Filed 2019·Application pending·0 cites
- 4943US2018346867A1Device For Reduced Oxygen Concentration Culture In Microfluidic SystemsHARVARD COLLEGE·Filed 2016·Application pending·0 cites
- 5043US2022267794A1Compositions, devices, and methods for treating fabry diseaseSIGILON THERAPEUTICS INC·Filed 2020·Application pending·0 cites
Showing the top 50 of 53 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Jeffrey Charles Way files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →